

In the adjuvant treatment of patients with completely resected EC or GEJC with residual pathologic disease following neoadjuvant CRT

Only OPDIVO[®] ...

The first and only immunotherapy to double median disease-free survival vs placebo in the adjuvant setting^{1*†}

INDICATION

*OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).¹

[†]**Primary analysis:** mDFS 22.4 mos (95% CI: 16.6–34.0) in all randomized patients with OPDIVO vs 11.0 mos (95% CI: 8.3–14.3) with placebo; HR=0.69 (95% CI: 0.56–0.85); *P*=0.0003¹

Please see [page 3](#) for trial design and additional efficacy data, including the primary endpoint for Checkmate 577.

CI=confidence interval; EC=esophageal cancer; GEJC=gastroesophageal junction cancer; HR=hazard ratio; mDFS=median disease-free survival; mo=month.

SELECT IMPORTANT SAFETY INFORMATION

Summary of Warnings and Precautions

- OPDIVO is associated with the following Warnings and Precautions: severe and fatal immune-mediated adverse reactions including pneumonitis, colitis, hepatitis and hepatotoxicity, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, other immune-mediated adverse reactions; infusion-related reactions; complications of allogeneic hematopoietic stem cell transplantation (HSCT); embryo-fetal toxicity; and increased mortality in patients with multiple myeloma when OPDIVO is added to a thalidomide analogue and dexamethasone, which is not recommended outside of controlled clinical trials.


Please see additional Important Safety Information for OPDIVO on pages 5-6 and US Full Prescribing Information for [OPDIVO](#).

OPDIVO[®]
(nivolumab)

INJECTION FOR INTRAVENOUS USE 10 mg/mL

In the adjuvant treatment of patients with completely resected EC or GEJC with residual pathologic disease following neoadjuvant CRT

Complement your treatment approach with OPDIVO® in the adjuvant setting for patients at high risk of recurrence¹⁻³



NCCN Category 1, Preferred⁴

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) recommends Nivolumab (OPDIVO) as a Category 1 adjuvant therapy option for patients with EC/GEJC (adenocarcinoma or squamous cell carcinoma) after neoadjuvant chemoradiation with R0 resection and residual disease.

Category 1 based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.⁴

- Please see the most current NCCN Guidelines[®] for a complete listing of all NCCN-recommended agents and other relevant information

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Esophageal and Esophagogastric Junction Cancers V.2.2022. ©National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 2, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org.

CRT=chemoradiotherapy; EC=esophageal cancer; GEJC=gastroesophageal junction cancer.

SELECT IMPORTANT SAFETY INFORMATION

Severe and Fatal Immune-Mediated Adverse Reactions

- Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.
- Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO. Early identification and management are essential to ensure safe use of OPDIVO. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment with OPDIVO. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
- Withhold or permanently discontinue OPDIVO depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed on page 6.

Please see additional Important Safety Information for OPDIVO on pages 5-6 and US Full Prescribing Information for [OPDIVO](#).


OPDIVO[®]
(nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL



In the adjuvant treatment of patients with completely resected EC or GEJC with residual pathologic disease following neoadjuvant CRT

OPDIVO® (nivolumab) doubled median disease-free survival vs placebo^{1,5}

Median disease-free survival* in all randomized patients^{1,5}



31% reduction in the risk of recurrence or death with OPDIVO vs placebo in the primary analysis¹

Primary analysis: mDFS benefit was observed regardless of tumor PD-L1 status^{2,6§}

- **PD-L1 ≥1% (n=129) mDFS: 19.7 mos** (95% CI: 11.3–NA) with OPDIVO vs **14.1 mos** (95% CI: 5.5–22.8) with placebo; unstratified HR=0.75 (95% CI: 0.45–1.24)^{2,6}
- **PD-L1 <1% (n=570) mDFS: 21.3 mos** (95% CI: 16.3–34.0) with OPDIVO vs **11.1 mos** (95% CI: 8.3–15.2) with placebo; unstratified HR=0.73 (95% CI: 0.57–0.92)^{2,6}
- **PD-L1 indeterminate/non-evaluable (n=95) mDFS: not reached** (95% CI: 13.3–NA) with OPDIVO vs **9.5 mos** (95% CI: 3.4–NA) with placebo; unstratified HR=0.54 (95% CI: 0.27–1.05)^{2,6}
- Based on an exploratory analysis²

14-month follow-up analysis: median DFS was 22.4 months with OPDIVO^{5,7||}

- **PD-L1 ≥1% (n=129) mDFS: 28.3 mos** (95% CI: 13.3–NA) with OPDIVO vs **10.2 mos** (95% CI: 5.5–22.8) with placebo; unstratified HR=0.68 (95% CI: 0.42–1.10)
- **PD-L1 <1% (n=567) mDFS: 20.8 mos** (95% CI: 16.0–33.7) with OPDIVO vs **11.0 mos** (95% CI: 8.0–15.1) with placebo; unstratified HR=0.70 (95% CI: 0.56–0.87)
- **PD-L1 indeterminate/non-evaluable (n=98) mDFS: 26.6 mos** (95% CI: 14.1–NA) with OPDIVO vs **9.9 mos** (95% CI: 3.4–NA) with placebo; unstratified HR=0.64 (95% CI: 0.34–1.20)

Checkmate 577 trial design: Checkmate 577 was a global, phase 3, randomized (2:1), double-blind trial evaluating OPDIVO (n=532) vs placebo (n=262) in patients with completely resected esophageal or gastroesophageal junction cancer who had residual pathologic disease following CRT. Key eligibility criteria included stage II/III EC or GEJC; adenocarcinoma or squamous cell carcinoma; neoadjuvant CRT and surgical resection; residual pathologic disease ≥ypT1 or ≥ypN1; and ECOG PS of 0 or 1. Patients were stratified by tumor PD-L1 status, pathologic lymph node status, and histology. Patients received either OPDIVO 240 mg IV infusion over 30 minutes or placebo IV infusion over 30 minutes every 2 weeks for 16 weeks, followed by OPDIVO 480 mg IV infusion over 30 minutes or placebo IV infusion over 30 minutes every 4 weeks until disease recurrence, unacceptable toxicity, or for up to 1 year in total duration. The primary endpoint was disease-free survival.^{1,2*}

*Per investigator assessment.¹ †The boundary for statistical significance at the pre-specified interim analysis required the P value to be less than 0.036.² ‡Extended follow-up analysis: median follow-up of 32.2 months.⁵ §Tumor PD-L1 status was evaluated using the IHC 28-8 pharmDx assay.² ||Vs 10.4 months with chemotherapy.⁵ CI=confidence interval; CRT=chemoradiotherapy; DFS=disease-free survival; EC=esophageal cancer; ECOG PS=Eastern Cooperative Oncology Group Performance Status; GEJC=gastroesophageal junction cancer; HR=hazard ratio; IHC=immunohistochemistry; IV=intravenous; mDFS=median DFS; mo=month; NA=not available; PD-L1=programmed death ligand 1.

SELECT IMPORTANT SAFETY INFORMATION

Serious Adverse Reactions

- In Checkmate 577, serious adverse reactions occurred in 33% of patients receiving OPDIVO (n=532). A serious adverse reaction reported in ≥2% of patients who received OPDIVO was pneumonitis. A fatal reaction of myocardial infarction occurred in one patient who received OPDIVO.

Common Adverse Reactions

- In Checkmate 577, the most common adverse reactions (≥20%) in patients receiving OPDIVO (n=532) were fatigue (34%), diarrhea (29%), nausea (23%), rash (21%), musculoskeletal pain (21%), and cough (20%).

Please see additional Important Safety Information for OPDIVO on pages 5-6 and US Full Prescribing Information for OPDIVO.





In the adjuvant treatment of patients with completely resected EC or GEJC with residual pathologic disease following neoadjuvant CRT

Dosage and administration

Flexible dosing schedules to meet the needs of your patients¹



- OPDIVO® (nivolumab) is administered over 30 minutes as an intravenous infusion¹
- Based on exploratory dose exposure-response relationships for efficacy and safety, OPDIVO 240 mg q2w and 480 mg q4w are predicted to be similar⁸

CRT=chemoradiotherapy; EC=esophageal cancer; GEJC=gastroesophageal junction cancer; q2w=every 2 weeks; q4w=every 4 weeks.

SELECT IMPORTANT SAFETY INFORMATION

Infusion-Related Reactions

- OPDIVO can cause severe infusion-related reactions. Discontinue OPDIVO in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions. In patients receiving OPDIVO monotherapy as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate trial in which patients received OPDIVO monotherapy as a 60-minute infusion or a 30-minute infusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369) of patients, respectively. Additionally, 0.5% (2/368) and 1.4% (5/369) of patients, respectively, experienced adverse reactions within 48 hours of infusion that led to dose delay, permanent discontinuation or withholding of OPDIVO.

Please see additional Important Safety Information for OPDIVO on pages 5-6 and US Full Prescribing Information for [OPDIVO](#).

OPDIVO
(nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

IMPORTANT SAFETY INFORMATION

Severe and Fatal Immune-Mediated Adverse Reactions

- Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.
- Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO® (nivolumab). Early identification and management are essential to ensure safe use of OPDIVO. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment with OPDIVO. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
- Withhold or permanently discontinue OPDIVO depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

Immune-Mediated Pneumonitis

- OPDIVO can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune-mediated pneumonitis occurred in 3.1% (61/1994) of patients, including Grade 4 (<0.1%), Grade 3 (0.9%), and Grade 2 (2.1%).

Immune-Mediated Colitis

- OPDIVO can cause immune-mediated colitis. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).

Immune-Mediated Hepatitis and Hepatotoxicity

- OPDIVO can cause immune-mediated hepatitis. In patients receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients, including Grade 4 (0.2%), Grade 3 (1.3%), and Grade 2 (0.4%).

Immune-Mediated Endocrinopathies

- OPDIVO can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Withhold OPDIVO depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated. Monitor patients for hyperglycemia

or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.

- In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred in 1% (20/1994), including Grade 3 (0.4%) and Grade 2 (0.6%).
- In patients receiving OPDIVO monotherapy, hypophysitis occurred in 0.6% (12/1994) of patients, including Grade 3 (0.2%) and Grade 2 (0.3%).
- In patients receiving OPDIVO monotherapy, thyroiditis occurred in 0.6% (12/1994) of patients, including Grade 2 (0.2%).
- In patients receiving OPDIVO monotherapy, hyperthyroidism occurred in 2.7% (54/1994) of patients, including Grade 3 (<0.1%) and Grade 2 (1.2%).
- In patients receiving OPDIVO monotherapy, hypothyroidism occurred in 8% (163/1994) of patients, including Grade 3 (0.2%) and Grade 2 (4.8%).
- In patients receiving OPDIVO monotherapy, diabetes occurred in 0.9% (17/1994) of patients, including Grade 3 (0.4%) and Grade 2 (0.3%), and 2 cases of diabetic ketoacidosis.

Immune-Mediated Nephritis with Renal Dysfunction

- OPDIVO can cause immune-mediated nephritis. In patients receiving OPDIVO monotherapy, immune-mediated nephritis and renal dysfunction occurred in 1.2% (23/1994) of patients, including Grade 4 (<0.1%), Grade 3 (0.5%), and Grade 2 (0.6%).

Immune-Mediated Dermatologic Adverse Reactions

- OPDIVO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes.
- Withhold or permanently discontinue OPDIVO depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information).
- In patients receiving OPDIVO monotherapy, immune-mediated rash occurred in 9% (171/1994) of patients, including Grade 3 (1.1%) and Grade 2 (2.2%).

Other Immune-Mediated Adverse Reactions

- The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received OPDIVO monotherapy or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions: *cardiac/vascular*: myocarditis, pericarditis, vasculitis; *nervous system*: meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; *ocular*: uveitis, iritis, and other ocular inflammatory toxicities can occur; *gastrointestinal*: pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis; *musculoskeletal and connective tissue*: myositis/polymyositis, rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatica; *endocrine*: hypoparathyroidism; *other (hematologic/immune)*: hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.

(continued on next page)

Please see additional Important Safety Information for OPDIVO on following page, and US Full Prescribing Information for OPDIVO.

OPDIVO[®]
(nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

IMPORTANT SAFETY INFORMATION (cont'd)

Severe and Fatal Immune-Mediated Adverse Reactions (cont'd)

Other Immune-Mediated Adverse Reactions (cont'd)

- Some ocular IMAR cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, which has been observed in patients receiving OPDIVO® (nivolumab), as this may require treatment with systemic corticosteroids to reduce the risk of permanent vision loss.

Infusion-Related Reactions

- OPDIVO can cause severe infusion-related reactions. Discontinue OPDIVO in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions. In patients receiving OPDIVO monotherapy as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate trial in which patients received OPDIVO monotherapy as a 60-minute infusion or a 30-minute infusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369) of patients, respectively. Additionally, 0.5% (2/368) and 1.4% (5/369) of patients, respectively, experienced adverse reactions within 48 hours of infusion that led to dose delay, permanent discontinuation or withholding of OPDIVO.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation

- Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with OPDIVO. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between OPDIVO and allogeneic HSCT.
- Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with OPDIVO prior to or after an allogeneic HSCT.

Embryo-Fetal Toxicity

- Based on its mechanism of action and findings from animal studies, OPDIVO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and for at least 5 months after the last dose.

Increased Mortality in Patients with Multiple Myeloma when OPDIVO is Added to a Thalidomide Analogue and Dexamethasone

- In randomized clinical trials in patients with multiple myeloma, the addition of OPDIVO to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.

Lactation

- There are no data on the presence of OPDIVO in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 5 months after the last dose.

Serious Adverse Reactions

- In Checkmate 577, serious adverse reactions occurred in 33% of patients receiving OPDIVO (n=532). A serious adverse reaction reported in ≥2% of patients who received OPDIVO was pneumonitis. A fatal reaction of myocardial infarction occurred in one patient who received OPDIVO.

Common Adverse Reactions

- In Checkmate 577, the most common adverse reactions (≥20%) in patients receiving OPDIVO (n=532) were fatigue (34%), diarrhea (29%), nausea (23%), rash (21%), musculoskeletal pain (21%), and cough (20%).

References: 1. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. *N Engl J Med.* 2021;384(13):1191-1203. 3. Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. *Ann Surg.* 2007;245(5):707-716. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.2.2022. ©National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 2, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. 5. Moehler M, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: 14-month follow-up of CheckMate 577. Presentation at ESMO 2021. Presentation 131P. 6. Data on file. NIVO 612. Princeton, NJ: Bristol-Myers Squibb Company; 2020. 7. Data on file. NIVO 0124. Princeton, NJ: Bristol-Myers Squibb Company; 2021. 8. Long GV, Tsykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. *J Ann Oncol.* 2018;29(11):2208-2213.

Please see additional Important Safety Information for OPDIVO on previous page, and US Full Prescribing Information for [OPDIVO](#).